ReviewMolecular brain2025
Early autism detection: a review of emerging technologies, biomarkers, and explainable AI approaches.
Review in Molecular brain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Peripheral blood mononuclear cell proteomic profiling reveals cytoskeletal- and chromatin-associated protein signatures in autism spectrum disorder.Brain, behavior, & immunity - health · 2026Article
- A Critical Synthesis of Machine Learning in Autism Spectrum Disorder Genomic Research: From Transcriptomics to Microbiome.Medeniyet medical journal · 2026Article
- Artificial-intelligence-based developmental screening for pre-school children (ages 3-6): a scoping review of deployed tools, clinical validity, equity, and implementation in guidance-center settings.Frontiers in psychology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism Spectrum Disorder (ASD) presents as a complicated neurodevelopmental disorder which leads to social communication challenges and repetitive behavioral patterns. Early identification of ASD is crucial to facilitate early intervention that can make a large positive impact on long-term developmental outcomes. With the advent of artificial intelligence (AI) and data-driven diagnoses, there is increased interest in combining machine learning methods with biological and behavioral signatures to detect early ASD. This review provides an overview of broad classes of biomarkers-behavioral, neuroimaging, genetic, and eye gaze-and their respective methodologies, clinical applications, and diagnostic accuracy. For each of these biomarker domains, the research gap has been identified as existing for instance limited interpretability in neuroimaging models, genomics-related ethical and data accessibility issues, and innovation saturation for behavioral measurement. A comparative analysis highlights eye gaze analysis as a promising but under-explored option, providing a balance of cost-effectiveness, non-invasiveness, and potential for real-time, objective measurement. In addition, the application of Explainable AI (XAI) methodologies across these biomarker fields is discussed in order to meet the pressing need for transparency, clinical confidence, and decision-making support. This review makes a final call for further exploration of eye gaze-based models enriched by XAI methods as a future research direction towards filling the gap between algorithmic innovation and real-world, interpretable diagnostics in the context of ASD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.